LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 249

Search options

  1. Book: Lung Cancer

    Lovly, Christine M / Carbone, David P / Minna, John D

    Disease Biology and Its Potential for Clinical Translation

    2022  

    Language English
    Size 274 p.
    Publisher Cold Spring Harbor Laboratory Press
    Document type Book
    Note PDA Manuell_14
    Format 184 x 262 x 18
    ISBN 9781621823735 ; 1621823733
    Database PDA

    Kategorien

    Order for free: Patron-Driven-Acquisition (PDA)

    This title is not yet in the ZB MED collection, but may be ordered for free via the ZB MED acquisition service PDA. The ordered item will be available in approximately one week.

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: Real-world patient characteristics and treatment patterns in US patients with advanced non-small cell lung cancer.

    Divan, Hozefa A / Bittoni, Marisa A / Krishna, Ashok / Carbone, David P

    BMC cancer

    2024  Volume 24, Issue 1, Page(s) 424

    Abstract: Background: Patients from non-small cell lung cancer (NSCLC) controlled clinical trials do not always reflect real-world heterogeneous patient populations. We designed a study to describe the real-world patient characteristics and treatment patterns of ... ...

    Abstract Background: Patients from non-small cell lung cancer (NSCLC) controlled clinical trials do not always reflect real-world heterogeneous patient populations. We designed a study to describe the real-world patient characteristics and treatment patterns of first-line treatment in patients in the US with NSCLC.
    Methods: This was an observational, retrospective cohort study based on electronic medical records of US adults with locally advanced or metastatic disease in the ConcertAI Patient360 NSCLC database who initiated first-line treatment with anti-programmed cell death protein 1/programmed cell death ligand 1 (PD-1/PD-L1) therapy between July 2016 and December 2020. The analysis used patient attributes, clinical characteristics, and treatments from each patient's medical records.
    Results: A total of 2175 patients were eligible for analysis. The median age was 68 years, and 26.2% of the patients were ≥75 years old. At treatment initiation, 96.4% and 3.6% of the patients had Stage 4 and Stage 3 (B or C) NSCLC, respectively. The most common histology type was nonsquamous adenocarcinoma (66.4%), and 19.8% had Eastern Cooperative Oncology Group performance status ≥2. Immunosuppressive medications were being used by 17.7% of patients, and 11.0% were immunocompromised. Almost all patients had metastases: 64.6% had 1, 23.2% had 2, and 8.0% had ≥3 metastatic sites. Brain metastases were present in 22.9% of patients. Treatment evolution was observed with first-line standard of care shifting from single-agent immunotherapy in 2016 (90.2%) to combination immunotherapy and chemotherapy in 2020 (60.2%).
    Conclusion: Between 2016 and 2020, the first-line treatment paradigm for advanced NSCLC in the US shifted from anti-PD-1/PD-L1 monotherapy to combination chemoimmunotherapy, with increasing biomarker testing. Further research in heterogeneous patient populations to characterize treatment strategies is warranted.
    MeSH term(s) Adult ; Humans ; Aged ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/metabolism ; Lung Neoplasms/drug therapy ; Lung Neoplasms/metabolism ; B7-H1 Antigen/metabolism ; Retrospective Studies ; Immunotherapy
    Chemical Substances B7-H1 Antigen
    Language English
    Publishing date 2024-04-06
    Publishing country England
    Document type Observational Study ; Journal Article
    ZDB-ID 2041352-X
    ISSN 1471-2407 ; 1471-2407
    ISSN (online) 1471-2407
    ISSN 1471-2407
    DOI 10.1186/s12885-024-12126-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Response to the Letter to the Editor Titled "First-Line Nivolumab Plus Ipilimumab With Chemotherapy for Metastatic NSCLC: The Updated Outcomes From CheckMate 9LA".

    Paz-Ares, Luis G / Carbone, David P

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2023  Volume 18, Issue 9, Page(s) e102–e103

    MeSH term(s) Humans ; Ipilimumab/therapeutic use ; Nivolumab/therapeutic use ; Lung Neoplasms/drug therapy ; Carcinoma, Non-Small-Cell Lung/drug therapy
    Chemical Substances Ipilimumab ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2023-08-19
    Publishing country United States
    Document type Letter ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2023.05.022
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Patients' voice and passion lead to successful clinical trial, KISEKI study; Comments on "A phase II study (WJOG12819L) to assess the efficacy of osimertinib in patients with EGFR mutation-positive NSCLC in whom systemic disease (T790M-negative) progressed after treatment with first- or second-generation EGFR TKIs and platinum-based chemotherapy".

    Furuya, Naoki / He, Kai / Carbone, David P

    Lung cancer (Amsterdam, Netherlands)

    2023  Volume 178, Page(s) 143–144

    MeSH term(s) Humans ; Lung Neoplasms/drug therapy ; Lung Neoplasms/genetics ; ErbB Receptors/genetics ; Platinum/therapeutic use ; Protein Kinase Inhibitors/adverse effects ; Mutation ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Carcinoma, Non-Small-Cell Lung/genetics ; Aniline Compounds/therapeutic use
    Chemical Substances ErbB Receptors (EC 2.7.10.1) ; osimertinib (3C06JJ0Z2O) ; Platinum (49DFR088MY) ; Protein Kinase Inhibitors ; Aniline Compounds ; EGFR protein, human (EC 2.7.10.1)
    Language English
    Publishing date 2023-02-24
    Publishing country Ireland
    Document type Clinical Trial, Phase II ; Letter
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2023.02.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2135: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 423: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Development of new techniques and clinical applications of liquid biopsy in lung cancer management.

    Chen, Kezhong / He, Yue / Wang, Wenxiang / Yuan, Xiaoqiu / Carbone, David P / Yang, Fan

    Science bulletin

    2024  

    Abstract: Lung cancer is an exceedingly malignant tumor reported as having the highest morbidity and mortality of any cancer worldwide, thus posing a great threat to global health. Despite the growing demand for precision medicine, current methods for early ... ...

    Abstract Lung cancer is an exceedingly malignant tumor reported as having the highest morbidity and mortality of any cancer worldwide, thus posing a great threat to global health. Despite the growing demand for precision medicine, current methods for early clinical detection, treatment and prognosis monitoring in lung cancer are hampered by certain bottlenecks. Studies have found that during the formation and development of a tumor, molecular substances carrying tumor-related genetic information can be released into body fluids. Liquid biopsy (LB), a method for detecting these tumor-related markers in body fluids, maybe a way to make progress in these bottlenecks. In recent years, LB technology has undergone rapid advancements. Therefore, this review will provide information on technical updates to LB and its potential clinical applications, evaluate its effectiveness for specific applications, discuss the existing limitations of LB, and present a look forward to possible future clinical applications. Specifically, this paper will introduce technical updates from the prospectives of engineering breakthroughs in the detection of membrane-based LB biomarkers and other improvements in sequencing technology. Additionally, it will summarize the latest applications of liquid biopsy for the early detection, diagnosis, treatment, and prognosis of lung cancer. We will present the interconnectedness of clinical and laboratory issues and the interplay of technology and application in LB today.
    Language English
    Publishing date 2024-04-01
    Publishing country Netherlands
    Document type Journal Article ; Review
    ZDB-ID 2816140-3
    ISSN 2095-9281 ; 2095-9273
    ISSN (online) 2095-9281
    ISSN 2095-9273
    DOI 10.1016/j.scib.2024.03.062
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.

    Divan, Hozefa A / Bittoni, Marisa A / Krishna, Ashok / Carbone, David P

    Lung cancer (Amsterdam, Netherlands)

    2023  Volume 179, Page(s) 107177

    Abstract: Objectives: Data to guide treatment selection in metastatic nonsquamous (mNSq) non-small cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are limited. We investigated patterns of treatment and clinical outcomes ... ...

    Abstract Objectives: Data to guide treatment selection in metastatic nonsquamous (mNSq) non-small cell lung cancer (NSCLC) after progression on current standard-of-care (SoC) treatment are limited. We investigated patterns of treatment and clinical outcomes following one or more disease progressions on SoC.
    Materials and methods: Electronic medical records in the ConcertAI Patient360 NSCLC database were analyzed for US adults with mNSq NSCLC who initiated treatment between 2016 and 2021. Analyses were conducted separately for patients who had ≥1 prior lines of therapy and progression(s) without (Cohort 1) or with (Cohort 2) evidence of targetable genetic alterations (EGFR, ALK, or ROS1). Outcomes included real-world progression-free survival (rwPFS) and overall survival (rwOS).
    Results: Cohorts 1 and 2 included 281 and 109 patients, respectively. In Cohort 1, subsequent treatment was most often with docetaxel monotherapy (18.5%) or docetaxel + ramucirumab (32.4%). Most patients in Cohort 2 received platinum-based doublet chemotherapy with (22.9%) or without (34.9%) immunotherapy. Median rwPFS and rwOS were 2.9 and 7.2 months, respectively, in Cohort 1, and 3.2 and 10.4 months in Cohort 2. Neither the addition of ramucirumab to docetaxel in Cohort 1 nor the addition of immunotherapy to chemotherapy in Cohort 2 was associated with a marked improvement in additional survival.
    Conclusion: Patients with progressive mNSq NSCLC most commonly received later-line docetaxel for cancer without driver mutations, or platinum-based chemotherapy (following one or more lines of tyrosine kinase inhibitor therapy) for cancer with driver mutations, consistent with guideline recommendations. Median survival was poor regardless of subsequent treatment, highlighting the need for more effective options.
    MeSH term(s) Adult ; Humans ; United States ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Lung Neoplasms/drug therapy ; Docetaxel/therapeutic use ; Protein-Tyrosine Kinases ; Proto-Oncogene Proteins ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use
    Chemical Substances Docetaxel (15H5577CQD) ; Protein-Tyrosine Kinases (EC 2.7.10.1) ; Proto-Oncogene Proteins
    Language English
    Publishing date 2023-03-20
    Publishing country Ireland
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 632771-0
    ISSN 1872-8332 ; 0169-5002
    ISSN (online) 1872-8332
    ISSN 0169-5002
    DOI 10.1016/j.lungcan.2023.107177
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2135: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 423: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: An era of lung cancer iconoclasts.

    Carbone, David P

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2014  Volume 9, Issue 4, Page(s) 436–437

    MeSH term(s) Humans ; Lung Neoplasms/prevention & control ; Preventive Medicine
    Language English
    Publishing date 2014-04
    Publishing country United States
    Document type Editorial
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1097/JTO.0000000000000121
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Genetic Ancestry Affects Somatic Alterations in Lung Cancers.

    Araujo, Luiz H / Cordeiro de Lima, Vladmir C / Carbone, David P

    Cancer discovery

    2021  Volume 11, Issue 6, Page(s) 1320–1321

    MeSH term(s) American Indians or Alaska Natives/genetics ; Carcinoma, Non-Small-Cell Lung/genetics ; Central America ; Genetic Predisposition to Disease ; Genomics ; Humans ; Lung Neoplasms/genetics ; South America
    Language English
    Publishing date 2021-06-02
    Publishing country United States
    Document type Letter
    ZDB-ID 2625242-9
    ISSN 2159-8290 ; 2159-8274
    ISSN (online) 2159-8290
    ISSN 2159-8274
    DOI 10.1158/2159-8290.CD-20-1861
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6916: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors.

    Memmott, Regan M / Wolfe, Adam R / Carbone, David P / Williams, Terence M

    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

    2021  Volume 16, Issue 7, Page(s) 1086–1098

    Abstract: Monoclonal antibodies that target immune checkpoint proteins, so-called immune checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in the treatment of lung cancer. Studies have revealed improved objective response ... ...

    Abstract Monoclonal antibodies that target immune checkpoint proteins, so-called immune checkpoint inhibitors, prevent tumor evasion of the immune system and are often effective in the treatment of lung cancer. Studies have revealed improved objective response rates, progression-free survival, and overall survival with immune checkpoint inhibitors when used in both first and subsequent-line settings. Unfortunately, only a subset of unselected patients with lung cancer responds to these therapies. An important area of ongoing research is to identify biomarkers that can predict which patients are most likely to derive clinical benefit. This review will discuss established and emerging biomarkers from some of the clinical trials that have demonstrated the efficacy of immune checkpoint inhibitors for the treatment of both NSCLC and SCLC.
    MeSH term(s) B7-H1 Antigen/therapeutic use ; Carcinoma, Non-Small-Cell Lung/drug therapy ; Humans ; Immune Checkpoint Inhibitors ; Immunotherapy ; Lung Neoplasms/drug therapy ; Progression-Free Survival
    Chemical Substances B7-H1 Antigen ; Immune Checkpoint Inhibitors
    Language English
    Publishing date 2021-04-09
    Publishing country United States
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2432037-7
    ISSN 1556-1380 ; 1556-0864
    ISSN (online) 1556-1380
    ISSN 1556-0864
    DOI 10.1016/j.jtho.2021.03.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6664: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)
    Zs.MO 652: Show issues

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Pursuing Better Biomarkers for Immunotherapy Response in Cancer Through a Crowdsourced Data Challenge.

    Vincent, Benjamin G / Szustakowski, Joseph D / Doshi, Parul / Mason, Michael / Guinney, Justin / Carbone, David P

    JCO precision oncology

    2022  Volume 5, Page(s) 51–54

    MeSH term(s) Biomarkers, Tumor/immunology ; Clinical Trials as Topic ; Crowdsourcing/methods ; Humans ; Immune Checkpoint Inhibitors/therapeutic use ; Immunotherapy ; Models, Biological ; Neoplasms/immunology ; Nivolumab/therapeutic use
    Chemical Substances Biomarkers, Tumor ; Immune Checkpoint Inhibitors ; Nivolumab (31YO63LBSN)
    Language English
    Publishing date 2022-01-07
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ISSN 2473-4284
    ISSN (online) 2473-4284
    DOI 10.1200/PO.20.00371
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top